Marat Shpolyansky
Psychiatric/Mental Health · Burbank, CANPI 1932450954
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.9% of the total across 261 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 10 manufacturers reported payments, led by Johnson & Johnson at 30.5% of the total. Among psychiatric/mental health clinicians in CA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 261 payments — averaging $16.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$1K
- AbbVie$827
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$580
- Alkermes, Inc.$461
- Sunovion Pharmaceuticals Inc.$292
- Otsuka America Pharmaceutical, Inc.$207
- plus $541 from 4 others
What the payments were for
- Food & beverage$4,13599%
- Education$471%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 106 | $1,275 |
| AbbVie | 41 | $827 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 37 | $580 |
| Alkermes, Inc. | 27 | $461 |
| Sunovion Pharmaceuticals Inc. | 14 | $292 |
| Otsuka America Pharmaceutical, Inc. | 10 | $207 |
| Indivior Inc. | 9 | $173 |
| Vanda Pharmaceuticals Inc. | 8 | $166 |
| Lundbeck LLC | 6 | $144 |
| Neurocrine Biosciences, Inc. | 3 | $59 |
How this compares
$4,182 in reported general payments places this provider in the 90th percentile of 2,433 psychiatric/mental health providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Adderall XrDextroamphetamine/Amphetamine | 11 | $2,441 |
| Divalproex Sodium | 13 | $391 |
| Quetiapine Fumarate | 17 | $303 |
| Escitalopram Oxalate | 15 | $215 |
| Gabapentin | 26 | $170 |
| Duloxetine Hcl | 17 | $140 |
| Mirtazapine | 23 | $134 |
| Buspirone Hcl | 12 | $73 |
Paid to pharmacies, not to this prescriber.
Other psychiatric/mental health in Burbank
- Carey MartinMillbrae$745K
- Liberty MaciasRedlands$288K
- Joshua BurgettSacramento$239K
- Jovita Ezirim-SalamialofojeLos Angeles$162K
- Angie-Kolleen TanThousand Oaks$159K
- Thy LamVista$121K
- Samantha PerkinsAnaheim$49K
- Yvette ElpidioOrange$43K
- Sarah KoLos Angeles$34K
- Jonathan LlamasPasadena$31K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.